Showing results (31-40 of 39) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Plos Computational Biology|April 9, 2010
A human-specific de novo protein-coding gene associated with human brain functionsChuan-Yun Li, Yong Zhang, Zhanbo Wang, et al.Frontiers in Oncology|November 5, 2021
Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten PatientsWenwen Zhang, Bingyang Hu, Jun Han, et al.Radiology|March 19, 2024
Multiparametric US for Identifying Metabolic Dysfunction-associated Steatohepatitis: A Prospective Multicenter StudyFangyi Liu, Mingsen Bi, Xiang Jing, et al.Journal of Medicinal Chemistry|February 20, 2024
Discovery of Novel N-(Anthracen-9-ylmethyl) Benzamide Derivatives as ZNF207 Inhibitors Promising in Treating GliomaMenghan Zhang, Yushi Ding, Mengkang Gao, et al.Nature Communications|August 29, 2020
Clinically applicable histopathological diagnosis system for gastric cancer detection using deep learningZhigang Song, Shuangmei Zou, Weixun Zhou, et al.BMJ Open|September 11, 2020
Automatic deep learning-based colorectal adenoma detection system and its similarities with pathologistsZhigang Song, Chunkai Yu, Shuangmei Zou, et al.Signal Transduction and Targeted Therapy|May 6, 2026
Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trialShichun Lu, Wenwen Zhang, Junfeng Li, et al.Journal for Immunotherapy of Cancer|September 20, 2023
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trialWenwen Zhang, Shuang Tong, Bingyang Hu, et al.Bioscience Trends|December 25, 2024
Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)Haowen Tang, Wenwen Zhang, Junning Cao, et al.Pageof 4